Abstract
Adult T-cell leukemia/lymphoma (ATL) is a malignancy of CD4(+) T cells. Pan-T markers such as CD2, CD3, and CD5 are expressed but most ATL cases lack CD7. Typical ATL cases are CD4(+)/CD8(−), but there are CD4(−)/CD8(+), CD4/8 double-positive, and double-negative cases. These CD8 antigens are induced on CD4 T cells. ATL cells express CCR4 and CD25, which are common in regulatory T cells. Furthermore, they express other regulatory T cell markers, such as GITR and CTLA4. These immunophenotypical similarities with regulatory T cells, along with the expression of FoxP3, a master regulator of regulatory T cell development, suggests that ATL cells may be derived from regulatory T cells. Because FoxP3 expression is induced by HBZ, the origin of ATL cells should be determined carefully in the future. Human T-cell leukemia virus type I (HTLV-I) infected cells alter their immunophenotype during the oncogenic process into ATL. CD3 is downregulated while cells infected with HTLV-1 proceed from an asymptomatic carrier state to ATL. CD7 and CD26 are also downregulated, whereas CADM1 expression is induced in this process. These immunophenotypic changes can be useful for detecting ATL cells and analyzing the oncogenic progression to ATL.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ohshima, K., Jafe, E.S. and Kikuchi M. Adult T-cell leukemia/lymphoma. In: WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 281–4.
Went P, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472–9.
Klemke CD, et al. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol. 2015;173(1):93–105.
Kamihira S, et al. Phenotypical diversity and prognosis of adult T-cell leukemia. Leuk Res. 1992;16(5):435–41.
Ramirez F, et al. Glucocorticoids induce the expression of CD8c chains on concanavalin A-activated rat CD4 + T cells: induction is inhibited by rat recombinant interleukin 4. J Exp Med. 1992;176(6):1551–9.
Yamada Y, et al. Established IL-2-dependent double-negative (CD4- CD8-) TCR alpha beta/CD3+ ATL cells: induction of CD4 expression. Br J Haematol. 1994;88(2):234–41.
Yaamada Y. Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. Blood. 1993;61(1):192–9.
Fazekas de St Groth B, Smith AL, Higgins CA. T cell activation: in vivo veritas. Immunol Cell Biol. 2004;82(3):260–8.
Shimabukuro-Vornhagen A, et al. Activated human B cells: stimulatory or tolerogenic antigen-presenting cells? Blood. 2009;114:746–7.
Triplett TA, et al. Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG. Eur J Immunol. 2012;42(7):1893–905.
Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol Biol. 2011;707:3–17.
Yodoi J, Maeda M. Discovery of ATL: an odyssey in restrospect. Int J Hematol. 2011;94(5):423–8.
Turturro F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007;7(1):11–7.
Tobinai K. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. Semin Hematol. 2010;47(Suppl 1):S5–7.
Berkowitz JL, et al. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin Immunol. 2014;155(2):176–87.
Kreitman RJ, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18(8):1622–36.
Kreitman RJ, et al. Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity. Clin Cancer Res. 2015;22:310–8.
Hanafusa T, et al. Flow cytometric immunophenotyping of adult T-cell leukemia/lymphoma using CD3 gating. Am J Clin Pathol. 2005;124(2):199–204.
Akl H, et al. HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation. Leukemia. 2007;21(4):788–96.
Akl H, et al. Progressive loss of CD3 expression after HTLV-I infection results from chromatin remodeling affecting all the CD3 genes and persists despite early viral genes silencing. Virol J. 2007;4:85.
Tian Y, et al. Leukemic T cells are specifically enriched in a unique CD3(dim) CD7(low) subpopulation of CD4(+) T cells in acute-type adult T-cell leukemia. Cancer Sci. 2011;102(3):569–77.
Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 2006;7(12):243.
Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702.
Imai T, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int J Immunol. 1999;11(1):81–8.
Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9.
Takashi Ishida AU, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10):3625–34.
Ohshima K, et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: analysis of prognosis. Int J Oncol. 2004;25(3):605–13.
Ishii T, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520–31.
Ishida T, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–42.
Ishida T, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672–82.
Ruckes T, et al. Autocrine antiapoptotic stimulation of cultured adultT-cell leukemia cells by overexpression of the chemokine I-309. Blood. 2001;98(4):1150–9.
Hasegawa H, et al. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood. 2000;95(1):30–8.
Harasawa H, et al. Survey of chemokine receptor expression reveals frequent co-expression of skin-homing CCR4 and CCR10 in adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2006;47(10):2163–73.
Horikawa T, et al. IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int Immunol. 2002;14(7):767–73.
Wang W, et al. Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2). J Biol Chem. 2000;275(29):22313–23.
Pan J, et al. Cutting edge: a novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J Immunol. 2000;165(6):2943–9.
Sakaguchi S, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490–500.
Ronchetti S, et al. Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells. J Immunol Res. 2015;2015:171520.
Takahashi T, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte–associated antigen 4. J Exp Med. 2000;192(2):303–9.
Kohno T, et al. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci. 2005;96(8):527–33.
Matsubara Y, et al. Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells. Leukemia. 2005;19(3):482–3.
Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity. 2013;38(3):414–23.
Karube K, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004;126(1):81–4.
Satou Y, et al. HTLV-1 modulates the frequency and phenotype of FoxP3 + CD4+ T cells in virus-infected individuals. Retrovirology. 2012;9:46.
Gaudray G, et al. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol. 2002;76(24):12813–22.
Satou Y, et al. HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog. 2011;7(2):e1001274.
Schneider YJ, et al. The role of receptor-mediated endocytosis in iron metabolism. Prog Clin Biol Res. 1982;91:495–521.
Trowbridge IS, Shackelford DA. Structure and function of transferrin receptors and their relationship to cell growth. Biochem Soc Symp. 1986;51:117–29.
Gatter KC, et al. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol. 1983;36(5):539–45.
Vidal C, et al. Human T lymphotropic virus I infection deregulates surface expression of the transferrin receptor. J Immunol. 1988;141(3):984–8.
Moura IC, et al. Aneutralizing monoclonal antibody (mAbA24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood. 2004;103(5):1838–45.
Yamazaki J, et al. Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma. Blood. 2009;114(13):2709–20.
Yonehara S, et al. A cell-killing monoclonal antibody (ANTI-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med. 1989;169(5):1747–56.
Kamihira S, et al. Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias. Br J Haematol. 1997;99(4):858–65.
Krueger A, et al. HTLV-1Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood. 2006;107(10):3933–9.
Okamoto K, et al. Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NF-kappaB. Genes Cells. 2006;11(2):177–91.
Wang W, et al. Human T-cell leukemia virus type 1 Tax-deregulated autophagy pathway and c-FLIP expression contribute to resistance against death receptor-mediated apoptosis. J Virol. 2014;88(5):2786–98.
Maeda T, et al. Fas gene mutation in the progression of adult T cell leukemia. J Exp Med. 1999;189(7):1063–71.
Sugahara K, et al. Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines. Int J Cancer. 1997;72(1):128–32.
Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol. 2012;34(3):176–84.
Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11(2):255–60.
Hasegawa H, et al. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand. Br J Haematol. 2005;128(2):253–65.
Ding J, et al. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J Biol Chem. 2012;287(1):641–9.
Murakami Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci. 2005;96(9):543–52.
Galibert L, et al. Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule. J Biol Chem. 2005;280(23):21955–64.
Watabe K, et al. IGSF4: a new intercellular adhesion molecule that is called by three names, TSLC1, SgIGSF and SynCAM, by virtue of its diverse function. Histol Histopathol. 2003;18(4):1321–9.
Sasaki H, et al. Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood. 2005;105(3):1204–13.
Nakahata S, et al. Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma. Leukemia. 2012;26(6):1238–46.
Nakahata S, et al. CADM1/TSLC1 is a novel cell surface marker for adult T-cell leukemia/lymphoma. J Clin Exp Hematop. 2012;52(1):17–22.
Kobayashi S, et al. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2014;20(11):2851–61.
Yamagishi M, et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell. 2012;21(1):121–35.
Asanuma S, et al. Adult T-cell leukemia cells are characterized by abnormalities of Helios expression that promote T cell growth. Cancer Sci. 2013;104(8):1097–106.
Takahashi R, et al. Epigenetic deregulation of Ellis Van Creveld confers robust Hedgehog signaling in adult T-cell leukemia. Cancer Sci. 2014;105(9):1160–9.
Kobayashi S, et al. Advanced human T-cell leukemia virus type 1 carriers and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry. Cancer Sci. 2015;106(5):598–603.
Iwata S, et al. CD26/dipeptidyl peptidase IV in context: the different roles of a multifunctional ectoenzyme in malignant transformation. J Exp Med. 1999;190(3):301–5.
Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008;29(6):295–301.
Jones D, et al. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral' blood. Am J Clin Pathol. 2001;115(6):885–92.
Bauvois B, et al. Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. Br J Cancer. 1999;79(7/8):1042–8.
Morrison ME, et al. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med. 1993;177(4):1135–43.
Amatya VJ, et al. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines. Oncol Rep. 2011;26(6):1369–75.
Tsuji T, et al. Clinical and oncologic implications in epigenetic down-regulation of CD26/dipeptidyl peptidase IV in adult T-cell leukemia cells. Int J Hematol. 2004;80(3):254–60.
Kamihira S, et al. Heterogeneity in clonal nature in the smoldering subtype of adult T-cell leukemia: continuity from carrier status to smoldering ATL. Int J Hematol. 2012;95(4):399–408.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Japan KK
About this chapter
Cite this chapter
Uchimaru, K. (2017). Immunophenotype. In: Watanabe, T., Fukushima, T. (eds) Adult T-cell Leukemia/Lymphoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56523-9_5
Download citation
DOI: https://doi.org/10.1007/978-4-431-56523-9_5
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-56521-5
Online ISBN: 978-4-431-56523-9
eBook Packages: MedicineMedicine (R0)